株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Abera Bioscience AB の製品パイプライン分析

Abera Bioscience AB - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 318949
出版日 ページ情報 英文 20 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Abera Bioscience AB の製品パイプライン分析 Abera Bioscience AB - Product Pipeline Review - 2015
出版日: 2015年03月26日 ページ情報: 英文 20 Pages
概要

Abera Bioscience AB はスウェーデンに本社を持つバイオテクノロジー企業であり、インフルエンザ、肺炎球菌疾患、結核、クラミジアなどに対するワクチンおよびワクチン開発技術、経口および経鼻投与の遺伝子組換え型生ワクチン、不活化ワクチン、抗体、治療用タンパク質の創薬、研究開発、生産を行っています。

当レポートでは、Abera Bioscience AB における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Abera Bioscience AB の基本情報

  • Abera Bioscience AB の概要
  • 主要情報
  • 企業情報

Abera Bioscience AB :R&Dの概要

  • 主な治療範囲

Abera Bioscience AB :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Abera Bioscience AB :パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Abera Bioscience AB :薬剤プロファイル

  • chlamydia vaccine
  • influenza vaccine
  • pneumococcal vaccine (multivalent)
  • tuberculosis vaccine

Abera Bioscience AB :パイプライン分析

  • 投与経路別
  • 分子タイプ別

Abera Bioscience AB :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06853CDB

Summary

Global Markets Direct's, 'Abera Bioscience AB - Product Pipeline Review - 2015', provides an overview of the Abera Bioscience AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Abera Bioscience AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Abera Bioscience AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Abera Bioscience AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Abera Bioscience AB's pipeline products

Reasons to buy

  • Evaluate Abera Bioscience AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Abera Bioscience AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Abera Bioscience AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Abera Bioscience AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Abera Bioscience AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Abera Bioscience AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Abera Bioscience AB Snapshot
    • Abera Bioscience AB Overview
    • Key Information
    • Key Facts
  • Abera Bioscience AB - Research and Development Overview
    • Key Therapeutic Areas
  • Abera Bioscience AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Abera Bioscience AB - Pipeline Products Glance
    • Abera Bioscience AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Abera Bioscience AB - Drug Profiles
    • Ab-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ab-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ab-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ab-04
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Abera Bioscience AB - Pipeline Analysis
  • Abera Bioscience AB - Pipeline Products by Route of Administration
  • Abera Bioscience AB - Pipeline Products by Molecule Type
  • Abera Bioscience AB - Dormant Projects
  • Abera Bioscience AB - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Abera Bioscience AB, Key Information
  • Abera Bioscience AB, Key Facts
  • Abera Bioscience AB - Pipeline by Indication, 2015
  • Abera Bioscience AB - Pipeline by Stage of Development, 2015
  • Abera Bioscience AB - Monotherapy Products in Pipeline, 2015
  • Abera Bioscience AB - Preclinical, 2015
  • Abera Bioscience AB - Discovery, 2015
  • Abera Bioscience AB - Pipeline by Route of Administration, 2015
  • Abera Bioscience AB - Pipeline by Molecule Type, 2015
  • Abera Bioscience AB - Dormant Developmental Projects,2015

List of Figures

  • Abera Bioscience AB - Pipeline by Top 10 Indication, 2015
  • Abera Bioscience AB - Pipeline by Stage of Development, 2015
  • Abera Bioscience AB - Monotherapy Products in Pipeline, 2015
  • Abera Bioscience AB - Pipeline by Top 10 Molecule Type, 2015
Back to Top